Blinatumomab As a Successful Bridge to Hematopoietic Stem Cell Transplant in a Down Syndrome Patient with Relapsed B-Precursor Acute Lymphoblastic Leukemia
Children with Down syndrome (DS) carry a 20-fold higher risk of developing acute lymphoblastic leukemia (ALL) than other children and have increased rates of treatment-related mortality (TRM) and relapse. The prognosis for relapsed DS-ALL patients is grim with long-term survival rates of 20%. Blinatumomab, a CD19/CD3 bispecific antibody, is FDA approved for relapsed pediatric pre-B ALL, and recently approved for patients with minimal residual disease (MRD). However there are few reports of the use of blinatumomab in DS-ALL patients, and no reports of blinatumomab as a bridge to stem cell transplant (SCT) in this population.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Mariel H. Smith, Peter G. Steinherz, Neerav Shukla, Christopher J. Forlenza, Susan E. Prockop, Kavitha Ramaswamy Tags: 494 Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Biology | Children | Down's Syndrome | Leukemia | Pediatrics | Stem Cell Therapy | Stem Cells | Transplants